|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **Mean** | | **SE** | | | **Distribution** | | **Source** |
| **Utility** | | | | | | | | |
| **Baseline utility** | | | | | | | | |
| AF well | 0.81 | | 0.08 | | | Beta | | Harrington 2013 [31] |
| **Chronic event utility** | | | | | | | | |
| Stroke | 0.63 | 0.03 | | | Beta | | Joundi 2022 [32] | |
| MI\* | 0.77 | 0.08\*\* | | | Harrington 2013 [31], Sullivan 2006 [33] | |
| ICH | 0.58 | 0.10 | | | Joundi 2022 [32] | |
| **Acute event disutilities** | | | | | | | | |
| Stroke\*\* | -0.25 | 0.03 | | | Beta | | Miller 2016 [38] | |
| CRB | -0.15 | 0.02 | | |
| MI | -0.11 | 0.01 | | |
| ICH\*\*\* | -0.27 | 0.03 | | |
| Systemic embolism | -0.11 | 0.01 | | |
| TIA | -0.01 | 0.01 | | |
| **Costs** | | | | | | | | |
| **Event costs** | | | | | | | | |
| Stroke | $17,698 | | $1,770 | | Gamma | | Patel 2014 [35], Sussman 2021 [36] | |
| CRB\*\*\*\* | $8,678 | | $868 | | Sussman 2021 [36] | |
| MI | $8,473 | | $847 | | Reddy 2015 [37] | |
| ICH | $31,137 | | $3,114 | | Miller 2016 [38] | |
| Systemic embolism | $9,160 | | $916 | | Clemens 2014 [39] | |
| TIA | $4,906 | | $491 | |
| **Maintenance costs** | | | | | | | | |
| Stroke | $20,878 | | | $2,088 | Normal | | Patel 2014 [35], Sussman 2021 [36] | |
| CRB | $0 | | | $0 | Miller 2016 [38] | |
| MI | $1,161 | | | $116 |
| ICH\*\*\* | $7,482 | | | $748 |
| **Treatment costs** | | | | | | | | |
| Warfarin | $16 | | | $0 | Uniform | | IBM Micromedex® database [40] (inflated to 2022 costs) | |
| Apixaban (5 mg bd) | $1,641 | | | $0 |
| Dabigatran (150 mg bd) | $1,568 | | | $0 |
| Rivaroxaban (20 mg od) | $1,279 | | | $0 |
| No treatment | $0 | | | $0 | Assumption | |
| **Monitoring costs** | | | | | | | | |
| Warfarin\*\*\*\*\*† | $623 | | | $62 | Normal | | Bobade 2019, [41] Dlott 2014 [42] | |
| Apixaban (5 mg bd) † | $44 | | | $4 | Medicare 2021 [43] | |
| Dabigatran (150 mg bd) † | $44 | | | $4 |
| Edoxaban (60 mg od) † | $44 | | | $4 |
| Rivaroxaban (20 mg od) † | $44 | | | $4 |
| No treatment | $0 | | | $0 | Assumption | |
| **Death costs** | | | | | | | | |
| Fatal stroke | $12,747 | | | $1,275 | Normal | | Harrington 2013 [31] | |
| Fatal CRB | $4,123 | | | $412 | Luengo-Fernandez 2021 [44] | |
| Fatal MI | $6,844 | | | $684 | Clemens 2014 [39] | |
| Fatal ICH | $46,636 | | | $4,664 | Miller 2016 [38] | |
| **Societal costs** | | | | | | | | |
| **Productivity losses** | | | | | | | | |
| Median weekly earnings by age, years | **Median** | | |  |  | |  | |
| 16–24 | $690 | | | $69 | Gamma | | BLS [52] | |
| 25–34 | $1003 | | | $100 |
| 35–44 | $1197 | | | $120 |
| 45–54 | $1224 | | | $122 |
| 55–64 | $1172 | | | $117 |
| 65+ | $991 | | | $99 |
| **Social care costs** | | | | | | | | |
| Stroke (annual cost for first year) | $6,995 | | | $700 | Gamma | | Sussman 2021 [36] | |
| Stroke (annual cost for subsequent years) | $3,721 | | | $372 | Assumption based on Xu 2018 [53] | |
| **Societal perspective** | | | | | | | | |
| **Informal care by caregivers (proportion of population in work by age, years)** | | | | | | | | |
| 16–24 | 51% | | | 5% | Normal | | BLS [54] | |
| 25–34 | 80% | | | 8% |
| 35–44 | 81% | | | 8% |
| 45–54 | 79% | | | 8% |
| 55–64 | 64% | | | 6% |
| 65+ | 19% | | | 2% |
| Proportion of stroke and TIA patients receiving informal care by age, years | | | | | | | | |
| 45–54 | 32% | | | 0.03 | Normal | | Ganapathy 2015 [55] | |
| 55–64 | 32% | | | 0.03 |
| 65–74 | 32% | | | 0.03 |
| 75–84 | 32% | | | 0.03 |
| 85+ | 32% | | | 0.03 |
| Number of hours per week of informal care | | | | | | | | |
| Stroke | 27.4 | | | 2.7 | Normal | | Ganapathy 2015 [55] | |
| MI | 6.7 | | | 0.7 | Irish Heart Foundation [56] | |
| TIA | 9 | | | 0.9 | HTA [45] | |
| **Proportion of patients leaving work due to illness** | **Median** | | |  | | | | |
| Stroke | 65% | | | 0.07 | Normal | | Smith et al. [57] | |
| MI | 36% | | | 0.04 | Song et al. [58] | |
| TIA | 47% | | | 0.05 | Smith et al. [57] | |
| **Discontinuation rates following a clinical event** | | | | | | | | |
| Stroke | 30% | | | 26% | Beta | | Lopez-Lopez 2017 [1] | |
| CRB | 30% | | | 26% |
| MI | 0% | | | 0% |
| ICH | 100% | | | 0% |
| Systemic embolism | 10% | | | 26% |
| TIA | 10% | | | 26% |
|  | | | | | | | | |